Mindera Health and Liviniti Partner to Improve the Management of Psoriasis With Precision Medicine

SergeVo/AdobeStock

Mindera Health recently announced its new partnership with Liviniti, a pharmacy benefit manager, to improve the management of patients with moderate to severe psoriasis. Mindera Health is known for its predictive test, Mind.Px, a dermal biomarker patch that quickly and painlessly extracts mRNA from the skin and is followed by transcriptomic analysis and machine learning-derived classifiers.

The new pilot program between Mindera Health and Liviniti will use Mind.Px to improve clinical outcomes while using Liviniti’s ability to lower biologic drug costs for self-funded patients.

According to Mindera Health, specialty drug spending for psoriasis is significantly increasing, and biologics are “often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year.” Additionally, successful patient responses to biologics are approximately 52%, which leads to increased trial-and-error treatments and health care expenses.

Mindera Health’s Mind.Px provides clinicians with applicable results with a 92% positive predictive value. The minimally invasive patch can capture over 7000 biomarkers per sample and is designed to predict a patient’s response to “expensive biologic drug classes” before selecting a biologic or moving forward with treatment.

“We are delighted to partner with a Pharmacy Benefit Manager like Liviniti to introduce precision medicine to psoriasis patients. We share the core value of introducing innovation to significant markets to decrease drug costs while improving patient outcomes,” said Ron Rocca, CEO of Mindera Health, in the news release.

Liviniti offers pass-through pricing within a transparent business model to help provide health savings to its members.

“Inflammatory conditions are a major cost trend driver in the specialty pharmacy space. Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members,” said LeAnn C. Boyd, CEO of Liviniti, in the news release.

Reference

Mindera Health launches program with innovative pharmacy benefit manager to improve management of moderate-to-severe psoriasis patients through precision medicine. News release. Mindera Health. February 29, 2024. Accessed February 29, 2024. https://minderahealth.com/mindera-health-launches-program-with-innovative-pharmacy-benefit-manager-to-improve-management-of-moderate-to-severe-psoriasis-patients-through-precision-medicine/